PATHOLOGY News & Analysis

Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.

Morningstar sees several reasons to expect a stronger recover than market consensus.

The proposed deal to create Australia’s largest pathology provider faces hurdles from the Healius board and regulators, says Morningstar.